Onco-Innovations Limited announced a study by its subsidiary Inka Health Corp. that advances the real-world applicability of lung cancer clinical trials, particularly for non-small cell lung cancer. The study, published in medRxiv, uses external data and expert knowledge to align clinical trial results with real-world patient outcomes, improving clinical decision-making and expanding access to therapies.

A phase 3 HARMONi-6 trial demonstrated that Ivonescimab in combination with chemotherapy significantly improved progression-free survival (PFS) in patients with advanced squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression status. The trial involved 532 patients across 66 clinical research centers in China. Ivonescimab was found to have a comparable safety profile to the control group and demonstrated potential to overcome the limitations of bevacizumab in treating squamous NSCLC.

Traws Pharma, Inc., previously Onconova Therapeutics (NASDAQ:TRAW), has appointed Iain Dukes as its Interim Chief Executive Officer, effective April 1, 2025. The company, valued at $10 million, is pursuing opportunities in antiviral drug markets, particularly bird flu and COVID-19 treatments. Traws Pharma is also preparing for a pre-IND meeting with the FDA and exploring long COVID studies. The company has announced a $50 million stock offering to support its operations.

The Global Cancer Biomarkers Market is projected to reach USD 32.5 billion by 2031, with a CAGR of 12.3% from 2024 to 2031. This growth is driven by advancements in AI-driven biomarker analysis, multi-omics approaches, and targeted therapies. The market focuses on biological molecules for cancer detection, diagnosis, prognosis, and treatment monitoring, including genetic, protein, and metabolic markers. Key players include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Enzo Biochem, Inc., Merck Millipore, and Micron Technology. Recent industry developments include partnerships between Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI), and OncoDNA and Eli Lilly Italia to enhance biomarker testing access for thyroid cancer patients in Italy.

The Global Myelodysplastic Syndrome Therapeutics market is projected to expand rapidly, with a Compound Annual Growth Rate (CAGR) of 13% from 2025 to 2032, reaching $12 billion by 2032. The market is segmented by type (chemotherapy drugs, immunosuppressive therapy, stem cell transplant, growth factors therapy, targeted therapy) and application (hospitals, specialty clinics, research institutes, biotech & pharma companies, home healthcare). Leading companies include Celgene Corporation, Takeda Pharmaceutical, Bristol-Myers Squibb, Novartis, Astex Pharmaceuticals, Otsuka Holdings, Geron Corporation, and Acceleron Pharma. Market drivers include rising prevalence of MDS, advancements in gene therapy and personalized medicine, increased government funding, and growth in clinical trials. Challenges include high treatment costs, limited awareness, regulatory hurdles, and limited donor availability for stem cell transplants. The Asia-Pacific region is expected to be the fastest-growing region.